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S U M M A R Y
Background: Liver cirrhosis is awell-known co-morbidity in prosthetic hip infection (PHI), but the results
of treatment and prognostic factors that predict outcomes of PHI in cirrhotic patients have not been
studied.
Methods: We performed a cohort study of patients with liver cirrhosis who contracted PHI and were
treated at our institution between January 1990 and December 2004.
Results: Of 349 ﬁrst-time episodes of PHI during the study period, 33 (9.5%) occurred in patients with
liver cirrhosis. Debridement with retention of the prosthesis (DWROP) was the initial treatment
modality for 24 (73%) episodes of PHI and cured the infection in seven (29%). A shorter median duration
of symptoms (5 vs. 14 days; p = 0.007) and absence of a sinus tract (p = 0.02) were associated with
successful treatment. Excision arthroplasty (EA) was required in 26 (79%) episodes and eradicated PHI in
24 (92%). In 20 patients who had reimplantation of a new prosthesis, the infection recurred in six (30%).
Patients who developed hepatic decompensation after reimplantation had a signiﬁcantly higher risk of
recurrent PHI than those who did not (relative risk 7.5; 95% conﬁdence interval 4.8–9.5; p = 0.018).
Conclusions: Liver cirrhosis is a common co-morbidity in patients with PHI treated at our institution.
DWROP should be considered only when there is no sinus tract and the duration of symptoms is very
short (less than 10 days). EA is an effective procedure to cure infection. However, reimplantation of hip
prosthesis in these patients carries a high risk of infection recurrence, especially in those who develop
hepatic decompensation.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Cirrhosis is the common end stage of many chronic liver
diseases. Viral hepatitis and excessive alcohol consumption, a
major cause of femoral head necrosis, are among the important
etiologies of cirrhosis.1,2 With an increasing prevalence of these
conditions and improved survival associated withmodernmedical
care, surgeons are increasingly treating patients with concomitant
liver cirrhosis. Approximately 10% of cirrhotic patients will
undergo surgery during the last two years of their life.3 Because
malnutrition, impaired immunity, coagulopathy, and metabolic
bone disease often develop secondary to liver cirrhosis, these
patients are at increased risk of complications following major
orthopedic surgery, such as total hip replacement.4–6
Ziser et al. reviewed 733 cirrhotic patients undergoing any type
of surgical procedure and reported a perioperative total complica-* Corresponding author. Tel.: +886 5 3621000x2855; fax: +886 5 3623005.
E-mail addresses: kc2672@adm.cgmh.org.tw, kc2672@hotmail.com
(K.-C. Huang).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.06.018tion rate of 30.1%.4 For these patients, the rate of infection-related
complications was 10.2%.4 Patients undergoing arthroplasty or
surgery for fracture of the hip had a signiﬁcantly higher
complication rate than those undergoing other types of surgery
(53.8% vs. 29.4%, p = 0.008).4 In two recent studies,5,6 infection was
reported as themost common complication and themajor cause of
prosthesis failure (10–22%) in cirrhotic patients undergoing hip
arthroplasty. These studies revealed markedly higher risks of
prosthetic hip infection (PHI) in patients with liver cirrhosis as
compared to non-cirrhotic patients in whom the incidence of PHI
was approximately 1%.4–7
Although cirrhosis of the liver is a well-known predisposing
factor for PHI, the outcome of PHI management in cirrhotic
patients, to our knowledge, has not been reported in the English
language literature. Therefore, this study was designed to
evaluate treatment outcomes among cirrhotic patients with PHI
and to identify prognostic factors that might lead to treatment
failure. The information from this study may be valuable in
improving the medical care of cirrhotic patients with PHI by
providing a guide for appropriate patient and treatment selection
in clinical practice.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
The Child–Turcotte–Pugh (CTP) scoring system
Clinical and laboratory measurements Points scored for increasing abnor-
malitiesa
1 2 3
Albumin (g/dl) >3.5 2.8–3.5 <2.8
Bilirubin (mg/dl) 1–1.9 2–2.9 3
PT (s prolonged) 1–4 4–6 >6
Ascites None Controlled Uncontrolled
Encephalopathy None Minimal Coma
PT, prothrombin time.
a Hepatic functional reservewas classiﬁed according to themeasured CTP scores:
class A, 5–6 points; class B, 7–9 points; class C, 10–15 points.
Table 2
Diagnostic criteria of cirrhosis-related complications
Complication Diagnostic criteria
Spontaneous bacterial
peritonitis (SBP)
Clinical signs of peritonitis plus
(1) PMN count in the ascites
>0.25109/l with or without
positive bacterial culture from
ascites, or (2) PMN count in the
ascites <0.25109/l but with
positive ascites bacterial culture11
Bleeding esophageal varices Clinical signs of hematemesis or
coffee-ground vomitus plus
endoscopic ﬁndings of active
bleeding or adherent clot on EV11
Hepatic encephalopathy According to the criteria proposed by
the working party at the 11th
World Congresses of
Gastroenterology, Vienna, 199812
Hepatorenal syndrome According to the criteria proposed by
the International Ascites Club.13
PMN, polymorphonuclear leukocyte; EV, esophageal varices.
Table 3
Demographic data and symptoms at presentation for 33 cirrhotic patients with
prosthetic hip infections (PHI) treated between 1990 and 2004
Variable Valuea
Age, median years (range) 47 (29–73)
Male gender 24 (73)
Follow-up, median months (range) 36 (7–72)
Etiology of liver cirrhosis
Viral hepatitis 10 (30)
Alcohol 5 (15)
Combined 17 (52)
Cryptogenic 1 (3)
CTP class at the time of infection
Class A 16 (48)
Class B 14 (42)
Class C 3 (9)
Reason for hip replacement
Femoral head necrosis 23 (70)
Osteoarthritis 7 (21)
Fracture 3 (10)
Type of prosthesis at the time of infection
Primary total hip arthroplasty 19 (58)
Revision total hip arthroplasty 9 (27)
Hemiarthroplasty 5 (15)
Duration of symptoms, median days (range) 11 (3–46)
Prosthesis age, median days (range) 107 (8–1320)
Presentation of infection
Discharging sinus 11 (33)
Purulent ﬂuid or pus in the joint 19 (58)
Fever (temperature 38.3 8C) 5 (15)
CTP, Child–Turcotte–Pugh scoring system.9
a Data are presented as number (%) of hips, unless otherwise indicated.
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2.1. Participating patients and inclusion/exclusion criteria
The study included all cirrhotic patients who were diagnosed
with ﬁrst-episode PHI and treated by the authors at Chang Gung
MemorialHospital between January1990andDecember2004. Liver
cirrhosiswas documented primarily by histological or perioperative
laboratory/imaging ﬁndings. For patients in whom liver biopsy had
not been performed, the diagnosis of liver cirrhosiswasmade on the
basis of at least two of the following ﬁndings: (1) abnormal liver
function test results (serum albumin 3.4 g/dl, international
normalized ration (INR) 1.3, or serum bilirubin 2 mg/dl), (2)
esophageal varices (EVs) on endoscopy, and (3) portal hypertension
suggested on imaging studies (ultrasonography or computed
tomography).8 Hepatic functional reserve was measured according
to theChild–Turcotte–Pugh (CTP) scoring system(Table1).9 PHIwas
deﬁned by the following criteria: (1) presence of a discharging sinus
communicatingwith the joint, (2) operativeﬁndingsofpurulence, or
(3) positive laboratory and histopathology tests,10 plus isolation of
pathogens from at least two positive results of cultures of joint
aspirate or intraoperative specimens. Patients were considered for
enrollment in this study if they met the above diagnostic criteria of
liver cirrhosis and PHI. Thosewith prior PHI treated elsewherewere
excluded from the study.
2.2. Deﬁnition of treatment outcome
‘Eradication of infection’ was considered when there was no
wound inﬂammation, the patient did not complain of pain, and
serial C-reactive protein (CRP) levels (recordedmonthly) remained
less than 15 mg/l for at least 3 months. ‘Persistent infection’ was
deﬁned as the occurrence of PHI due to the same microorganism
isolated at the time of original debridement. ‘Recurrence of
infection’ was deﬁned as any PHI that occurred after completion of
a staged prosthetic removal and reimplantation surgery, regardless
of the microorganism. ‘Hepatic decompensation’ was deﬁned as
the presence of at least one of the following cirrhosis-related
complications: (1) spontaneous bacterial peritonitis (SBP), (2) EV
bleeding, (3) hepatic encephalopathy, and (4) hepatorenal
syndrome or (5) an increase in the CTP score of 2 points or more
for any reason (Table 2).11–13
2.3. Patient characteristics and study signiﬁcance
We summarized the collected data at the time of study
enrollment, which included demographic data, status of cirrhosis
according to the CTP scoring system, past surgical history of the
hip, presenting signs/symptoms and duration of PHI, laboratory
ﬁndings, bacteriologic results, presence or absence of hepatic
decompensation, and treatment outcomes such as eradication,
persistence or recurrence of infection. These data were analyzed tostudy the relationships between patient characteristics and
treatment outcomes. Results of this analysis may provide clues
for the development of appropriate patient and treatment
selection criteria in future studies.
2.4. Statistical analyses
The survival rate free of infection was estimated using the
Kaplan–Meier survival method, reported with 95% conﬁdence
intervals (CIs). Chi-square analysis or Fisher’s exact test was used
where appropriate for analyzing categorical data. For numerical
data, the independent t-test or the nonparametric Mann–Whitney
U-test was used for between-group comparisons. Statistical
signiﬁcance was deﬁned as p < 0.05. Because of the small sample
size in this study, univariate rather than multivariate analyses
were performed. All statisticswere two-sided and performed using
SAS software (version 9.1.3, SAS Inc., Cary, NC, USA).
Table 4
Microbiological ﬁndings of 33 episodes of prosthetic hip infections (PHI) in cirrhotic
patients treated between 1990 and 2004
Infecting microorganisms Valuea
Staphylococcus aureus, methicillin-resistant 9 (27)
Staphylococcus aureus, methicillin-sensitive 8 (24)
Staphylococcus, coagulase-negative 6 (18)
Pseudomonas aeruginosa 3 (9)
Streptococcus 2 (6)
Escherichia coli 2 (6)
Enterococcus 1 (3)
Klebsiella pneumoniae 1 (3)
Polymicrobial 1 (3)
a Data are presented as number (%) of hips.
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3.1. Analyses of patient characteristics and related variables
Thirty-three ﬁrst-time episodes of PHI among 33 patients with
liver cirrhosis were enrolled in this 15-year-long study. This
accounted for 33 (9.5%) of 349 episodes of PHI encountered at our
institution during the study period (Table 3). Twenty-four (73%)
episodes of PHI occurred in male patients, and the median age at
the time of diagnosis was 47 years (range 29–73 years). Nineteen
(58%) were infections of primary total hip arthroplasty, nine (27%)
were of revision total hip arthroplasty, and ﬁve (15%) were of hip
hemiarthroplasty. The most common reason for hip replacement
was femoral head necrosis (23 hips; 70%). Status of liver cirrhosis
in this study, according to the CTP classiﬁcation, was class A in 16
patients (48%), class B in 14 patients (42%), and class C in three
patients (10%) at the time of diagnosis.
The median prosthesis age, deﬁned as duration from prosthesis
implantation to diagnosis of PHI, was 107 days (range 8–1320
days). The median duration of symptoms as reported by patients
was 11 days (range 3–46 days). Sinus tracts were present in 11
episodes of PHI (33%), a body temperature of 100.9 8F (38.3 8C)
was observed in ﬁve (15%), and intraoperative ﬁndings of turbid
ﬂuid/frank pus in the hip joint was seen in 19 (58%) of the 33 PHI
episodes.
PHI in the current studywas caused primarily by Gram-positive
microorganisms (Table 4), with staphylococcal infections being the
most common (23 episodes; 70%).Meanwhile, of the 33 episodes of
PHI, Gram-negative microorganisms caused six (18%) infections
and one infection was polymicrobial (3%).
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Figure 1. Flow chart of treatment modalities for 33 episodes of prosthetic h3.2. Analyses of therapeutic modality and related outcome
The number of PHI episodes treated with each therapeutic
modality is outlined in Figure 1. DWROP was the initial treatment
for 24 episodes (73%) of PHI inwhich no loosening of the prosthesis
was found during the operation. The other nine (27%) episodes of
PHI were treated with immediate excision arthroplasty (EA) with
removal of all components. DWROP typically included dislocation
of the prosthetic hip, complete exposure of the hip joint, removal of
the inﬂamed soft tissues and bone, and debridement of prosthesis–
bone interfaces. On completion of the procedure, implantation of
antibiotic-loaded cement beads within the joint was performed in
11 (46%) of the 24 hips. DWROP resolved seven (29%) of the 24 PHI
episodes, in which no evidence of infectionwas seen at amedian of
34 (range 12–60) months following surgery. Persistent infection
was noted in 17 (71%) hips requiring further surgical treatment toExcision arthroplasty
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ip infection (PHI) in cirrhotic patients treated between 1990 and 2004.
Table 5
Selected variables in 24 patients initially treated by debridement with retention of the prosthesis (DWROP)
Variable Eradication of infection (n=7)a Persistence of infection (n=17)a p-Value
Age, median years (range) 48 (29–71) 53 (36–73) 0.62
Male gender 6 (86) 11 (65) 0.38
CTP score 6 (5–9) 6 (5–12) 0.40
Diabetes mellitus 2 (29) 3 (18) 0.61
Cemented prosthesis 1 (14) 2 (12) 0.99
Multiple hip surgery before infection (2 times) 2 (29) 6 (35) 0.75
Prosthesis age, median days (range) 66 (25–780) 121 (8–1320) 0.24
Duration of symptoms, median days (range) 5 (3–10) 14 (5–46) 0.007b
Presence of a sinus tract 0 9 (53) 0.02b
Fever (38.3 8C) 1 (14) 2 (12) 0.99
Use of antibiotic beads 4 (57) 7 (41) 0.66
Antibiotic therapy duration, median days (range) 37 (29–60) 47 (26–63) 0.15
MRSA infection 3 (43) 4 (24) 0.37
Gram-negative infection 1 (14) 3 (18) 0.84
CTP, Child–Turcotte–Pugh scoring system;9 MRSA, methicillin-resistant Staphylococcus aureus.
a Data are presented as number (%) of hips, unless otherwise indicated.
b The difference is signiﬁcant (p<0.05).
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was 52% (95% CI 46–56%) at 6 months, 38% (95% CI 31–44%) at 1
year, and 28% (95% CI 19–37%) at 3 years following DWROP.
Twenty-six (79%) patients underwent EA with removal of all
components, which included 17 delayed and nine immediate types
of procedure (with or without previous DWROP, respectively). For
these patients PHI was eradicated in 24 out of 26 cases (92%). Two
patients (8%) had a persistent infection despite EA, repeated
surgical debridement, and prolonged antibiotic therapy. Both
patients were classiﬁed as class C according to the CTP scoring
system, with PHI due to Staphylococcus aureus. At the time of
writing this article, one patient had died of sepsis and the otherwas
hospitalized with a draining wound. Four patients in whom PHI
was eradicated by EA did not undergo reimplantation of hip
prosthesis. Extensive bone and soft tissue loss prohibited a stable
reimplantation in three patients, and the reasonwas not elucidated
from the medical records of the other patient.
Twenty patients underwent reimplantation of hip prosthesis
after a median interim period of 101 days (range 81–160 days)
following EA. Of these, the infection recurred in six patients (30%),
occurring at a median of 26 months (range 8–37 months) after
reimplantation. The infecting microorganism isolated in recurrent
cases was the same as that causing the original PHI in two patients
and was different in four patients. The estimated survival rate free
of recurrent infection was 72% (95% CI 64–80%) at 3 years and 63%
(95% CI 55–71%) at 5 years following staged exchange arthroplasty
(initial EA and later reimplantation of prosthesis).Table 6
Risk factors for recurrence of infection in 20 patients undergoing reimplantation
Variable Recurrence of infection
CTP score at reimplantation 6.5 (5–9)
CRP level at reimplantation (mg/l) 11.5 (4–15)
ESR level at reimplantation (mm/h) 19 (11–38)
Duration of interim period (days) 107 (94–160)
Use of interim spacers 2 (33)
Antibiotics in bone cement for reimplantation 1 (17)
Diabetes mellitus 3 (50)
Development of hepatic decompensation 5 (83)
SBP 2 (33)
EV bleeding 4 (67)
Encephalopathy 2 (33)
Hepatorenal syndrome 2 (33)
Increase of CTP score 2 4 (67)
Development of hepatocellular carcinoma 1 (17)
CTP, Child–Turcotte–Pugh scoring system;9 CRP, C-reactive protein; ESR, erythrocyte s
a Data are presented as median (min, max) or number (%).
b The difference is signiﬁcant (p<0.05).Fifteen patients had died at the time of writing this article. The
causes of death were cirrhosis-related complications in seven
patients and hepatocellular carcinoma (HCC) in four. Four deaths
occurred due to the infection. The survival rate following
development of PHI was 91% (95% CI 86–95%) at 1 year, 73%
(95% CI 65–81%) at 3 years, and 35% (95% CI 22–48%) at 5 years.
3.3. Analyses of predictors of treatment outcome
The results of univariate analysis of patients who were treated
with DWROP are presented in Table 5. A shorter duration of
symptoms before treatment (5 vs. 14 days; p = 0.007) and absence
of a sinus tract (p = 0.02) were associated with successful
treatment (eradication of infection). Patient age, gender, CTP
score, history of diabetes, multiple prior hip surgery, type of
prosthesis ﬁxation, prosthesis age, presence of fever, use of
antibiotic-loaded cement beads in the joint, duration of antibiotic
therapy, and the infecting microorganisms were not found to be
statistically signiﬁcant risk factors.
The results of univariate analysis of patients who were treated
with staged exchange arthroplasty are presented in Table 6.
Patients who developed hepatic decompensation after reimplan-
tation had a signiﬁcantly increased risk of recurrent PHI than those
who did not (relative risk 7.5; 95% CI 4.8–9.5; p = 0.018). However,
the occurrence of individual cirrhosis-related complications was
not statistically signiﬁcant as an independent risk factor for
recurrence of infection. Other parameters such as CTP score, CRP(n=6)a No recurrence of infection (n=14)a p-Value
6 (5–9) 0.64
8.5 (2–17) 0.55
23 (5–56) 0.57
99 (79–138) 0.16
5 (36) 0.9
3 (21) 0.8
3 (21) 0.3
3 (21) 0.018b
1 (7) 0.2
3 (21) 0.12
2 (14) 0.54
0 0.07
3 (21) 0.12
3 (21) 0.8
edimentation rate; SBP, spontaneous bacterial peritonitis; EV, esophageal varices.
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implantation, duration of interim period, use of an interim spacer,
use of antibiotics in bone cement for prosthesis ﬁxation, history of
diabetes, and development of HCC were also found not to be
statistically signiﬁcant risk factors.
4. Discussion
Overall, the outcome of management for cirrhotic patients with
PHI in this study was disappointing: only seven (21%) out of 33
patientshad retained theiroriginalhipprosthesesat theﬁnal follow-
up, and 21 (64%) out of 33 patients, after a variety of surgical
proceduresandprolongedantibiotic therapies,hada functioninghip
prosthesis free of infection. These ﬁndings highlight the difﬁculty in
medical care of cirrhotic patients with PHI and the importance of
evaluating predictors of treatment outcome for these patients.
Unfortunately, little data are available in the literature. Because
cirrhotic patients are at an increased risk ofmortality andmorbidity
after surgery,8 we believe that information from this study may be
valuable in improving treatment for cirrhotic patients with PHI by
providinga guide for the infectious disease specialist andorthopedic
surgeon. To our knowledge, this is the ﬁrst study in the English
language literature to document treatment outcomes of PHI in
patients with liver cirrhosis.
In the present study, the authors report that DWROP was most
effective in eradicating infection in cirrhotic patients with PHI who
presentedwith a short duration of symptoms and/or the absence of
a sinus tract . These observations are consistent with previous
studies on prosthetic joint infections (PJI) performed in non-
cirrhotic patients. Burger et al. investigated implant salvage in
infected total knee arthroplasty and revealed that a short duration
(<2 weeks) of symptoms before initial debridement and the
absence of a sinus tract were associated with a higher probability
of successful treatment.14 Tattevin et al. found a shorter interval
(<5 days) from the onset of symptoms to debridement of the PJI in
13 (38%) patients who were successfully treated with DWROP,
compared with a much longer median interval (54 days) in the
remaining 21 (62%) patients with treatment failure.15 More
recently, in amultivariate analysis of 99 episodes of PJI, Marculescu
et al. reported that the presence of a sinus tract and duration of
symptoms of 8 days are linked to an increased risk of treatment
failure following DWROP by a factor of 3 and 2, respectively.16
Based on the results of our study and those of other researchers, the
authors recommend that DWROP should not be attempted in
chronically infected prosthetic hips and in those who present with
a sinus tract because a failed attempt incurs high surgical risk
associated with multiple surgical procedures in these cirrhotic
patients.
The role of rifampin in the treatment of staphylococcal
biomaterial infections has been studied extensively as it has
shown bactericidal activity against staphylococcal bioﬁlm.17–20 In
a randomized, placebo-controlled, double-blind clinical trial in 24
patients with culture-proven staphylococcal infections associated
with stable orthopedic implants, Zimmerli et al. reported that all
12 (100%) patients treatedwith a rifampin-containing regimen and
only seven (58%) of those who did not receive rifampin were cured
without removal of the device.20 In our study, which included
episodes of PHI that occurred in patients with liver cirrhosis, none
of our patients received rifampin-containing regimens either as a
part of initial therapy or for long-term antimicrobial suppression
because of the well-known hepatic toxicity of rifampin. This fact
may be responsible in part for the low success rate associated with
DWROP in this case series.
EA remains a reliable method to eradicate PHI in cirrhotic
patients, which effectively controlled the infection in 24 (92%) out
of 26 patients undergoing the procedure in our study. Persistentinfection was seen in two patients who had class C liver cirrhosis
despite complete removal of all components and prolonged
antibiotic therapy. Radical debridement and transposition of
muscle ﬂap (modiﬁed vastus lateralis ﬂap, for example) as a dead
space ﬁller might be an option for these recalcitrant cases.21 As
noted by Huang et al., this procedure is a valuable and convenient
tool for orthopedic surgeons and should be characterized as a
technique situated between traditional limb-salvaging procedures
(EA, for example) and disarticulation of the hip joint.21 Although
this extensive surgical procedure might be relatively contra-
indicated bymedical conditions in cirrhotic patients with terminal
stage disease, it would be worthwhile to investigate in future
studies if muscle ﬂap transfer attempts improve or worsen
subsequent results of recalcitrant PHI in cirrhotic patients.
Reimplantation of a new prosthesis is often requested by
patients when PHI is eradicated by EA because of poor functional
status associated with pseudoarthrosis. However, we have found
that reimplantation carries a high risk of recurrence of infection in
patients with liver cirrhosis. PHI recurred in six of our cirrhotic
patients (30%) at a median of 26 months after reimplantation, in
contrast to the high success rates of 88–96% at 4- to 10-year follow-
up periods for two-stage exchange hip arthroplasty in non-
cirrhotic patients.22–24 Pathogenesis of infection in liver cirrhosis is
related to impaired removal capacity of the reticuloendothelial
system, a consequence of hepatic failure.25 Deﬁcient neutrophil
recruitment and altered phagocytic activity of neutrophils and
macrophages are also suggested to contribute to bacterial infection
in patients with cirrhosis.26
The incidence of hepatic decompensation after reimplantation
was found to be the only risk factor contributing to PHI recurrence,
at a high relative risk of 7.5. This ﬁnding mirrored the fact that the
extent of hepatic dysfunction was the most important factor
contributing to the development of PHI in cirrhotic patients. Given
that cirrhotic patients tend to haveworsening liver function during
the longitudinal follow-up period, we recommend close monitor-
ing of hepatic functional reserve and cirrhosis-related complica-
tions. Early identiﬁcation and prompt treatment of PHI in cirrhotic
patients may offer the best chance to preserve their functioning
prosthetic hips.
Cirrhotic patients usually have a shortened life expectancy.27 In
this case series, 15 (45%) out of 33 patients died at an average of 37
months after diagnosis of PHI. Four patients died of an HCC and
seven other patients died of cirrhosis-related complications. Many
of our patients experienced repeated admissions for the treatment
of HCC and various cirrhosis-related complications. Therefore, the
beneﬁts of reimplantation of a new hip prosthesis should be
cautiously weighed against reduced life expectancy, increased
surgical risk, and a high rate of PHI recurrence
This investigation has several key limitations, including the
small number of cases, retrospective study design, diversity of
treatment methods, and lack of a control group or non-cirrhosis
cohort information and multivariate analyses. Additional studies
(large-scale prospective randomized clinical trials with an
appropriate control group) are necessary to determine whether
or not the recommended patient and treatment selection criteria
can improve medical care of cirrhotic patients with PHI.
5. Conclusions
In this study, the authors found that liver cirrhosis is a common
co-morbidity of PHI at our institution. Early identiﬁcation and
prompt DWROP can salvage the prosthesis in patients with a short
duration of symptoms (less than 10 days) and the absence of a
sinus tract. EA with removal of the infected components is often
required and is a reliable method to control PHI in cirrhotic
patients. However, we emphasize that reimplantation of a new hip
P.-H. Hsieh et al. / International Journal of Infectious Diseases 14 (2010) e1054–e1059 e1059prosthesis is associated with a high rate of recurrent PHI. Patients
should be informed appropriately before surgery.
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